Stevanato Group S.p.A.
STVNHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South. The $5.23B market capitalization puts STVN squarely in mid-cap range for its industry. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Market Cap
$5.23B
Beta
0.78
P/E (TTM)
33.05
P/E (Fwd)
22.99
EPS (TTM)
$0.58
EPS (Fwd)
$0.83
ROE
9.6%
ROA
5.3%
Cash
$112.3M
Total Debt
$450.6M
Free CF
-$57.1M
52W Change
-23.0%
Annual Financials
Cash vs Debt
Stevanato Group S.p.A. carries $450.6M in total debt against $112.3M in cash reserves — debt is roughly 4.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$57.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 9.6% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $983.7M (2022) to $1.19B (2025), reflecting a 21% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing STVN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.